Education
About Us
Working with TipRanks
Follow Us
Tenax Therapeutics (TENX)
NASDAQ:TENX
TENX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.77 - $7.89
Previous CloseN/A
Volume25.45K
Average Volume (3M)38.24K
Market Cap
$25.77M
Enterprise Value$123.62M
Total Cash (Recent Filing)$837.17K
Total Debt (Recent Filing)$7.20K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
May 20, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.31
Shares Outstanding3,970,385
10 Day Avg. Volume27,342
30 Day Avg. Volume38,242
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap4.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.51
Forecast
1Y Price Target
$25.00Price Target Upside285.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Tenax Therapeutics News
PremiumPre-Earnings
Is TENX a Buy, Before Earnings?
PremiumCompany Announcements
Tenax Therapeutics Appoints Interim CFO Thomas McGauley---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTenax remains on track to complete expanded enrollment in the Phase III LEVEL study evaluating levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.
FundingThe company announced entry in a private placement financing with RTW Investments, resulting in gross proceeds of roughly $25 million that it expects to accelerate the registrational LEVEL program.
Market PerformanceTenax shares are up roughly 69% over the past 6 months, and additional upside to shares is seen based on the top-line LEVEL readout in mid-2026.
Bears Say
Clinical Trial ResultsIn the Ph2 HELP trial, IV levosimendan failed its primary endpoint of pulmonary capillary wedge pressure during exercise vs. baseline.
Clinical Trial RisksIn the downside scenario in which the Ph3 trial fails, TENX shares could potentially gap down to the low single digits.
Regulatory ChallengesTENX will have to conduct a second Ph3 trial in order to meet FDA’s request for subject drug exposure.
---
Ownership Overview
0.25% Insiders
1.63% Mutual Funds
26.74% Other Institutional Investors
70.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $2.77 and its highest was $7.89 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $25.77M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is May 20, 2025 which is in 49 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on Mar 25, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.425 by $0.245.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.41.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 3,970,385 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.425. Following the earnings report the stock price went down -2.077%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
---
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
---
TENX Stock 12 Month Forecast
Average Price Target
$25.00
▲(285.21% Upside)
Technical Analysis
Ovid Therapeutics
―
VYNE Therapeutics
―
PolyPid
―
Cognition Therapeutics
―
CytoMed Therapeutics Limited
―
Best Analysts Covering TENX
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+17.23%
reiterated a buy rating 5 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +17.23% per trade.
---